Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137

Neurosci Lett. 2013 Jan 4;532:33-8. doi: 10.1016/j.neulet.2012.08.065. Epub 2012 Sep 13.

Abstract

Objective: The Schizophrenia Psychiatric Genome-wide Association (GWAS) Consortium recently reported on five novel schizophrenia susceptibility loci. The most significant finding mapped to a micro-RNA, MIR-137, which may be involved in regulating the function of other schizophrenia and bipolar disorder susceptibility genes.

Method: We genotyped 821 patients with confirmed DSM-IV diagnoses of schizophrenia, bipolar affective disorder I and schizoaffective disorder for the risk SNP (rs1625579) and investigated the clinical profiles of risk allele carriers using a within-case design. We also assessed neurocognitive performance in a subset of cases (n=399) and controls (n=171).

Results: Carriers of the risk allele had lower scores for an OPCRIT-derived positive symptom factor (p=0.04) and lower scores on a lifetime measure of psychosis incongruity (p=0.017). Risk allele carriers also had more cognitive deficits involving episodic memory and attentional control.

Conclusion: This is the first evidence that the MIR-137 risk variant may be associated with a specific subgroup of psychosis patients. Although the effect of this single SNP was not clinically relevant, investigation of the impact of carrying multiple risk SNPs in the MIR-137 regulatory network on diagnosis and illness profile may be warranted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Bipolar Disorder / genetics
  • Case-Control Studies
  • Cognition Disorders / genetics*
  • Genetic Association Studies
  • Genotype
  • Heterozygote
  • Humans
  • MicroRNAs / genetics*
  • Polymorphism, Single Nucleotide
  • Psychotic Disorders / genetics
  • Schizophrenia / genetics*
  • Schizophrenic Psychology*
  • Young Adult

Substances

  • MIRN137 microRNA, human
  • MicroRNAs